On July 2, KPMG China unveiled its inaugural China HealthTech 50 report and list at an event in Beijing. Hundreds of healthcare technology leaders, academics, and industry experts attended the event to exchange perspectives on the future development of the sector.
Genepoint was named to the China HealthTech 50 list in recognition of its innovative technologies and capabilities in the life sciences industry.
The event explored several important themes shaping the future of healthcare technology, including healthcare innovation ecosystems, emerging artificial intelligence trends, and digital and intelligent operations.
According to KPMG China, participating companies were assessed through a multi-dimensional evaluation process. The methodology combined KPMG's evaluation model, detailed information submitted by each company, on-site visits, and expert scoring. The final list recognizes companies demonstrating both strong overall capabilities and significant growth potential.
Genepoint develops intelligent low-temperature biospecimen storage solutions for research institutions, hospitals, biobanks, pharmaceutical companies, and other life science organizations. By combining automation, cryogenic engineering, and digital sample management, the company helps customers protect, manage, and use valuable biological samples more securely and efficiently.
Genepoint's inclusion in the inaugural China HealthTech 50 list reflects recognition of the company's achievements in technology development, practical application, and contribution to the life sciences industry.
Looking ahead, Genepoint will continue to advance automated biospecimen storage technologies and develop smarter, more reliable solutions for the global research and life sciences community. The company remains committed to supporting the industry's transition toward more intelligent, secure, and efficient sample management.
